A Deep Dive On Early Time-to-Tocilizumab

Article

The latest episode of the ASTCT Talks features Rahul Banerjee, MD, on bone marrow transplant and CAR-T therapy.

On the latest episode of ASTCT Talks, Rahul Banerjee, MD, advanced fellow of Bone Marrow Transplant/CAR-T Therapy in the Department of Medicine at the University of California (UC) San Francisco, and Nina Shah, MD, associate professor in the Department of Medicine at UC San Francisco, discuss their paper “Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.” The paper was co-authored by Shah and Banerjee, along with several colleagues, and was published in ASTCT’s Transplantation and Cellular Therapy Journal in March.

Tune in

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. Like what you hear? Subscribe to ASTCT Talks and never miss an episode.

Reference

Banerjee R, Marsal J, Huang CY, et al. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021;27(6):477.e1-477.e7. doi:10.1016/j.jtct.2021.03.004

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content